to instantly read 150+ free stories & 250-word summaries of all our stories

Cheap Enough

What is hurting Indian pharma more—misinformation or price control?

The industry body is lashing out at the regulator for stifling a growing industry. But the members say the drug companies are doing just fine

20/04/17

Ruhi Kandhari

In hushed tones, senior executives of some of the largest pharmaceutical companies say that they want to work with the regulator and abide by the law but Dilip G Shah has taken the conflict very personally

The public posturing of the IPA, which is in sharp contrast to its own report, shows the extent of the misinformation being floated

The industry agrees that in the last three years, price regulation has affected them only marginally, not nearly enough to reverse the growth

To look into the matter, the DoP has set up a committee, whose objective is to ensure enhanced access to drugs and a streamlined price control mechanism

nose-156596_1280.png

On 13 April, a day before the Easter weekend, many drug manufacturers went on their breaks feeling a little agitated but mostly helpless. It was the day, the spokesperson of the Indian Pharmaceutical Alliance (IPA), representing its (invite only) members—over 20 large companies including Sun Pharma, Dr Reddy’s, Lupin and Cipla—went public with his anger….

To access this post, you must purchase Monthly Recurring, Quarterly or Weekly Product.

Read the full story. Create a free account.

Or subscribe. Why? Let us explain.

Already Registered?

Related stories

More stories in /Healthcare & /Reportage

See all in Analysis, Reportage, Startups & Technology

Want to read this story for free right now? Just

Read the full story instantly.
Just enter your email address.

Or subscribe. Why? Let us explain.

Or

By registering, you will be signed-up for an account which gives you access to a free story published once a week and archives of all our free stories. You will also receive a daily newsletter sent to your inbox. To unsubscribe, please visit the profile section in your account.

What you get

Access all free stories

100+ archived free stories, and all upcoming ones too.

Paid story summaries

Read an exclusive 200 word summary for all our paid stories.

Daily Newsletters

Our world-renowned emails, in your inbox, every day.

Or get full access to all our stories

About subscriptions

Already Registered? Login

Questions?

What is The Ken?

The Ken is a subscription-driven media site. We write one story a day (weekdays only). These stories have sharp, original insights on technology, business, science and healthcare from India.

Why do I have to sign up to read your stories?

Our stories are not free. Well, some select stories are. But, a significant part of what we write at The Ken is for subscribers only. We put in a lot of effort and resources in writing our stories and believe that you must pay for good journalism.
Hence, our three plans. 1) The annual membership
2) The free sign up
3) The recurring quarterly subscription

On journalism and why you should pay for it, if you haven’t already seen it, here’s a great explainer from John Oliver.

So, one must pay for journalism?

Yes.

How many stories will I get if I take an annual membership?

200+ stories.

And, in the free sign up?

Four stories every month.

Do I get a refund?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am not getting my daily emails. Do I have to whitelist emails from The Ken?

An added benefit of your subscription (free/paid) are the daily personalised emails. These emails, at times, might end up in your spam/junk folder due to emojis, attachments or images. In case you’re not receiving these emails, it might help to whitelist us. If the problem still persists, write to us at [email protected].

Why am I unable to access the archives?

Full and unrestricted access to our archives is a feature of our annual membership.

My payment is not going through, what can I do?

Please write to us at [email protected] detailing the payment error or queries.

See all FAQs

    See all results for Ken

    No results found for Ken.